Compositions and methods for treatment of cardiovascular disorders

1. A method for treating damaged cardiovascular tissue of a subject, the method comprising the steps of:

providing a mixed liquid exosome augmented extracellular matrix (ECM) composition, said exosome augmented ECM composition comprising acellular ECM from a mammalian tissue source and a plurality of exogenous exosomes isolated from mesenchymal stem cells (MSCs),

said acellular ECM adapted to induce a first level of stem cell proliferation, bioremodeling of damaged cardiovascular tissue and regeneration of new cardiovascular tissue, when said acellular ECM is disposed proximate said damaged cardiovascular tissue,

said plurality of exogenous exosomes adapted to induce a second level of stem cell proliferation, bioremodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue, when said plurality of exogenous exosomes is disposed proximate said damaged cardiovascular tissue;

providing a left ventricular assist device (LVAD) that supports heart function by reducing mechanical load on a left ventricle of a subject's heart when said LVAD is in communication with said subject's left ventricle; and

delivering said exosome augmented ECM composition proximate said damaged cardiovascular tissue associated with said subject's cardiovascular disorder in conjunction with providing said support of said subject's heart function with said LVAD, wherein, a third level of stem cell proliferation, bioremodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue is induced, said third level of induced stem cell proliferation, bioremodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue being greater than the sum of said first level of induced stem cell proliferation, bioremodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue, and said second level of induced stem cell proliferation, bioremodeling of said damaged cardiovascular tissue and regeneration of new cardiovascular tissue.

2. The method of claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa, urinary bladder submucosa, stomach submucosa, cardiac tissue, placental tissue, omentum tissue and kidney tissue.

3. The method of claim 1 , wherein said plurality of exogenous exosomes comprise an encapsulated growth factor selected from the group consisting of exogenous bFGF, TGF-β, and VEGF.

4. The method of claim 1 , wherein said plurality of exogenous exosomes comprise an encapsulated inflammation modulating agent selected from the group consisting of an interleukin, transcription factor RNA and micro RNA (miRNA).

5. The method of claim 1 , wherein said delivery of said exosome augmented ECM composition and said provision of said heart function support are performed within a first period of time of less than 10 minutes of each other.

6. The method of claim 1 , wherein said method further comprises the step of providing a needle-based injection system that is adapted to induce a biological insult in tissue when in communication therewith.

7. The method of claim 6 , wherein said biological insult is induced in said damaged cardiovascular tissue with said needle-based injection system in conjunction with said delivery of said exosome augmented ECM composition and said provision of said heart function support.

8. The method of claim 7 , wherein said biological insult comprises piercing said subject's damaged cardiovascular tissue.

9. The method of claim 7 , wherein said delivery of said exosome augmented ECM composition, said induced biological insult and said heart function support are performed within a first period of time in the range of 5-60 minutes of each other.